PEA2 Antibody

What is PEA2 and what are the different research contexts in which "PEA2" appears?

PEA2 appears in multiple research contexts that should not be confused:

• PEA2 Cell Line: An adherent human ovarian adenocarcinoma cell line derived from peritoneal ascites. It is part of a panel of ovarian adenocarcinoma cell lines and was collected from a patient who had relapsed after treatment with cisplatin and prednimustine .

• Pea2 Protein in Yeast: A protein localized to sites of polarized growth in yeast, with antibodies specifically developed to recognize this protein. These antibodies are used to analyze budding and mating phenotypes of pea2Δ strains and to study the subcellular localization of Pea2p .

• PLA2R Antibody (often confused with "PEA2"): Anti-phospholipase A2 receptor (PLA2R) antibodies that are used in diagnosing primary membranous nephropathy .

• Proximity Extension Assay (PEA): A technology that uses antibody pairs linked to DNA tags to measure proteins, not to be confused with PEA2 cell lines or antibodies .

How do researchers distinguish between different types of antibodies in PLA2R testing?

Researchers can utilize both monoclonal and polyclonal antibodies for PLA2R testing. A monoclonal antibody (designated 2E1 in some research systems) can be used as a catching antibody, while a polyclonal sheep anti-phospholipase A2 antibody labeled with europium can serve as the detecting antibody in time-resolved fluoroimmunoassay (TR-FIA) . The monoclonal antibody belongs to subclass I of murine IgG, and its specificity can be confirmed through multiple methods:

• Immunohistochemistry of pancreatic and other tissues

• Immunoblotting of crude aqueous extract of human pancreas

• Immunoblotting of purified human pancreatic phospholipase A2

• Time-resolved fluoroimmunoassay (TR-FIA)

What are the reference ranges for anti-PLA2R antibody tests and how should they be interpreted?

The reference ranges for anti-PLA2R antibody tests using ELISA are:

• <14 RU/mL: Negative

• 14 to 19 RU/mL: Borderline

• ≥20 RU/mL: Positive

It's important to note that this test should not be used as a stand-alone diagnostic tool but as an adjunct to other clinical information. A diagnosis of primary or secondary membranous nephropathy should incorporate clinical symptoms, physical examination findings, and additional laboratory tests when appropriate .

How are PEA2 cell lines utilized in ovarian cancer research models?

PEA2 cell lines serve as valuable research tools for studying:

• Mechanisms of estrogen action on ovarian adenocarcinoma tumor cells

• Drug efficacy and toxicity of estrogen protagonists

• Treatment resistance models, as PEA2 was derived from a patient who had relapsed after treatment with cisplatin and prednimustine

• Comparative studies with the PEA1 cell line (derived from the same patient but at a different disease stage)

The cell line exhibits poor growth in semi-solid medium (agar) and has adherent growth properties, making it suitable for certain in vitro experimental designs . When designing experiments with PEA2 cell lines, researchers should consider its origins from a poorly differentiated adenocarcinoma and its derivation from a treatment-relapsed case.

What methodologies are used for generating and validating antibodies with custom specificity profiles?

Researchers employ several sophisticated approaches to generate antibodies with custom specificity profiles:

• Phage display experiments: These can be used to select antibody libraries against various combinations of ligands, providing training and test sets for building computational models .

• Computational optimization: Using energy functions associated with each binding mode to design sequences that either:

  • Create cross-specific sequences by jointly minimizing functions associated with desired ligands

  • Generate highly specific sequences by minimizing functions for desired ligands while maximizing those for undesired ligands

• Selection against different complexes: For example, selections against "Black" (one DNA hairpin on beads), "Blue" (another DNA hairpin on beads), or "Mix" (mixture of both complexes) .

• Pre-selection depletion: Incubating phages with naked beads to deplete the antibody library of non-specific binders before the main selection .

• Multi-round selection: Performing multiple rounds of selection with amplification steps in between to enrich for desired binders .

How can the Proximity Extension Assay (PEA) be applied in antibody-based proteomics research?

The Proximity Extension Assay (PEA) offers a powerful methodology for antibody-based proteomics research:

• Principle: PEA translates protein information by linking protein-specific antibodies to DNA-encoded tags. Matched pairs of oligonucleotide-labeled antibodies bind to target antigens in a pairwise manner .

• Probe Generation:

  • Probes are generated from paired antibodies (matched monoclonal antibodies, split polyclonal antibody, or a mix)

  • One antibody is coupled to a sequence containing Illumina's P5 and Rd1SP sequence

  • The other antibody contains a common sequence used as a primer binding site

  • Both probes contain assay-specific barcodes and a hybridization site

• High-throughput capabilities: When combined with next-generation sequencing readout, PEA can enable parallel measurement of nearly 1,500 proteins in 96 samples, generating close to 150,000 data points per run .

• Performance characteristics:

  • Exceptional readout specificity and sensitivity (sub-pg/ml)

  • High multiplex assays with coverage across a broad dynamic range (~9 log)

  • Minimal sample consumption

How should researchers design experiments to monitor PLA2R antibodies in membranous nephropathy patients over time?

When designing longitudinal studies to monitor anti-PLA2R antibody levels in membranous nephropathy patients, researchers should consider:

• Assay selection: ELISA assays are preferred for monitoring patients with membranous nephropathy over time for trends in anti-PLA2R antibody levels, though high concordance exists between ELISA and indirect immunofluorescence assay results .

• Sampling timeline: Since titer changes (increase, decrease, or disappearance) generally precede clinical status changes, establish a sampling schedule that can capture these predictive changes before clinical manifestations appear .

• Clinical correlation: Include systematic collection of clinical data (proteinuria levels, renal function parameters, treatment modifications) to correlate with antibody level changes .

• Predictive value assessment: Design the study to evaluate the predictive value of antibody titer determination with respect to:

  • Clinical remission

  • Disease relapse

  • Risk assessment after kidney transplantation

• Control cohorts: Include patients with secondary membranous nephropathy and other glomerular diseases as controls, as 70-75% of primary membranous nephropathy patients are PLA2R-positive .

What experimental approaches can be used to distinguish between primary and secondary membranous nephropathy?

Distinguishing between primary and secondary membranous nephropathy requires a comprehensive experimental approach:

• Anti-PLA2R antibody testing: Anti-PLA2R antibodies are highly specific for primary membranous nephropathy (pMN) and can be detected in 70-75% of pMN cases .

• Renal biopsy analysis: Histopathological examination remains the gold standard. The test can be used in patients with biopsy-proven membranous nephropathy to determine if a specific autoantibody is present .

• Alternative approaches: In patients without renal biopsy but with clinical pictures consistent with membranous nephropathy, anti-PLA2R antibody testing can provide valuable diagnostic information .

• Comprehensive clinical evaluation: Assessment should include serological tests for secondary causes (lupus, hepatitis, malignancy), as a diagnosis should not be made on a single test result .

• Negative result interpretation: Absence of circulating anti-PLA2R autoantibodies does not rule out a diagnosis of primary MN, necessitating additional investigative approaches .

How can researchers develop and validate antibodies for specific recognition of Pea2 protein in yeast?

Based on the research methodology described for Pea2 protein antibody development:

• Epitope selection: Researchers successfully used a peptide corresponding to the final carboxy 20 amino acids of Pea2p for antibody generation .

• Validation strategies: Multiple validation methods should be employed:

  • Western blot analysis to confirm specific recognition of the protein

  • Verification that antibodies don't recognize background bands (except those caused by secondary antibodies)

  • Confirmation that bands recognized by antisera are missing in extracts from deletion strains

• Immunofluorescence applications: When using these antibodies for immunofluorescence:

  • Grow cells to early log phase

  • Fix with formaldehyde

  • Apply standard immunofluorescence techniques as described by Pringle et al. (1989)

How should researchers interpret changes in anti-PLA2R antibody titers in relation to clinical outcomes?

Interpretation of anti-PLA2R antibody titer changes requires sophisticated analysis:

• Titer dynamics: Changes in antibody titers generally precede changes in clinical status, providing a valuable predictive tool. Researchers should look for:

  • Increasing titers: May predict disease relapse

  • Decreasing titers: May predict movement toward remission

  • Disappearance of antibodies: May indicate complete remission

• Treatment response assessment: Monitor antibody levels to evaluate therapy outcome, as changes in titers have high predictive value for clinical remission, relapse, or risk assessment after kidney transplantation .

• Integration with clinical data: Always integrate antibody data with clinical symptoms, physical examination findings, and other laboratory tests when interpreting results for individual patients .

• Borderline results: Results in the 14-19 RU/mL range should be interpreted with caution and in the context of the complete clinical picture .

What analytical approaches are used in computational design of antibodies with custom specificity profiles?

Advanced computational approaches for designing antibodies with custom specificity profiles include:

• Binding mode identification: Identifying different binding modes, each associated with particular ligands against which the antibodies are either selected or not .

• Energy function optimization: Optimizing energy functions associated with each binding mode to:

  • For cross-specific antibodies: Jointly minimize energy functions associated with desired ligands

  • For highly specific antibodies: Minimize energy functions for desired ligands while maximizing those for undesired ligands

• Model training: Using data from phage display experiments to train computational models that can disentangle binding modes even when associated with chemically very similar ligands .

• Sequence prediction: Predicting novel antibody sequences not present in the training set with customized specificity profiles, either with specific high affinity for particular target ligands or with cross-specificity for multiple target ligands .

• Experimental validation: Testing computationally designed variants to assess the model's capacity to propose novel antibody sequences with the desired specificity characteristics .

What are common challenges in working with PEA2 cell lines and how can they be addressed?

When working with PEA2 cell lines, researchers should be aware of several challenges:

• Growth characteristics: PEA2 exhibits poor growth in semi-solid medium (agar), which may affect certain experimental applications. Alternative growth matrices may need to be explored for specific applications .

• Model system limitations: As PEA2 is derived from a patient who relapsed after treatment, it may exhibit distinct phenotypes compared to treatment-naive cell lines. Comparative studies with PEA1 (from the same patient but pre-treatment) may help establish treatment-induced changes .

• Heterogeneity considerations: As with any cancer cell line, heterogeneity may exist within the population. Single-cell approaches may be needed for certain applications to account for this heterogeneity.

• Growth conditions: Adherent growth properties require appropriate culture surfaces and conditions to maintain cellular characteristics and experimental reproducibility .

• Authentication: Regular authentication is essential to prevent cross-contamination or drift issues that can affect experimental outcomes.

What methodological considerations are important when using antibodies for time-resolved fluoroimmunoassay (TR-FIA)?

When implementing time-resolved fluoroimmunoassay with antibodies like those against phospholipase A2:

• Antibody pair selection: The combination of a monoclonal antibody as the catching antibody and a polyclonal antibody labeled with europium as the detecting antibody has proven effective .

• Validation procedures: Confirm specificity through multiple methods:

  • Immunohistochemistry

  • Immunoblotting

  • Control TR-FIA experiments

• Reference range establishment: Compare results from healthy subjects and patients with the condition of interest (such as acute pancreatitis for phospholipase A2) to establish appropriate reference ranges .

• Screening protocol optimization: When generating new monoclonal antibodies, effective screening of hybridomas for antibody production can be achieved using TR-FIA methodologies .

• Antibody characterization: Determine antibody class and subclass (e.g., subclass I of murine IgG) to understand potential applications and limitations .